Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

Pliant Therapeutics (PLRX) announced two PLN-101095 poster presentations at the Society for Immunotherapy of Cancer meeting, taking place November 4–8, 2026.

Rhea-AI Summary

Pliant Therapeutics (PLRX) announced two PLN-101095 poster presentations at the Society for Immunotherapy of Cancer meeting, taking place November 4–8, 2026. The meeting is at the Phoenix Convention Center in Phoenix, Arizona.

The November 6 poster addresses integrin targeting and immune checkpoint inhibition, with results obtained through a National Cancer Institute collaboration. The November 7 poster concerns plasma biomarkers and response to immune checkpoint inhibition in patients receiving PLN-101095. FORTIFY, the ongoing Phase 1a/1b trial, is enrolling its Phase 1b cohorts in non-small cell lung cancer, tumors with high tumor mutational burden, and clear cell renal cell carcinoma. Treatment starts with PLN-101095 alone before pembrolizumab is added.

Key Terms

pharmacokinetics, open-label, dose-escalation, immune checkpoint inhibitor, +1 more

5 terms

pharmacokinetics medical

"safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

open-label medical

"Phase 1a/1b open-label, dose-escalation and indication expansion trial"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

dose-escalation medical

"open-label, dose-escalation and indication expansion trial"

Dose-escalation is the part of an early-stage clinical trial where researchers gradually increase a drug’s dose in small groups of participants to find the safest and most effective amount. Think of it like turning up the volume slowly to find the sweet spot: investors watch these results closely because they reveal safety risks, potential effectiveness, and how quickly a drug can move to later trials or approval, all of which affect the development timeline and commercial prospects.

immune checkpoint inhibitor medical

"patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

non-small cell lung cancer medical

"three cohorts of patients with non-small cell lung cancer (NSCLC)"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41^st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona.

Poster Presentations

Title: Selective targeting of integrins αvβ8 and αvβ1 improves anti-tumor responses mediated by immune checkpoint inhibition

Poster:	615
Presenter:	Nika Rajabian, Ph.D., Postdoctoral Fellow, National Cancer Institute
Date:	Friday, November 6, 2026, 12:15 – 1:45 p.m. and 5:30 – 7:30 p.m. Mountain Time
Location:	North Building - Lower Level - Exhibition Halls 4-6

*The above presentation includes results that were obtained under a collaboration agreement between the National Cancer Institute and Pliant Therapeutics.

Title: Plasma biomarkers of immune activation predict sensitization to immune checkpoint inhibition (ICI) in patients with advanced solid tumors receiving dual αvβ8/αvβ1 integrin inhibitor PLN-101095

Poster	546
Presenter:	Martin L. Decaris, Ph.D., Vice President, Translational Sciences, Pliant Therapeutics
Date:	Saturday, November 7, 2026, 12:00 – 1:30 p.m. and 6:40 – 8:10 p.m. Mountain Time
Location:	North Building - Lower Level - Exhibition Halls 4-6

FORTIFY - PLN-101095 Phase 1a/1b Indication Expansion Trial

PLN-101095 is currently being evaluated in a Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in the Phase 1b trial portion of FORTIFY consisting of three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of α_vß₈ and α_vß₁ integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1a/1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes as well as other cell types.

For additional information on Pliant, visit www.PliantRx.com and follow us on X, LinkedIn and Facebook.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com